Upload
lethuy
View
237
Download
9
Embed Size (px)
Citation preview
McNeal
Gross appearanceappearance of Hyperplastic prostateprostate
Mcneal
20 65% 25% 10%70 50%
2-5 cc 2 5 cc, 2cc 0.5cc
(0.15mg/ml)
80 90%80 90%
(5-alpha reductase)
755 0-7 8-19 20-35 20 35
51
Q1Q1
0 1 2 3 4 5
Q22 0 1 2 3 4 5
Q3Q3
0 1 2 3 4 5
Q4
0 1 2 3 4 5
Q5
0 1 2 3 4 5
Q6 0 1 2 3 4 5
Q7 5Q7
0 1 2 3 45
(
0-7 8 198-1920-35 20 35
::::
Adapted from Nordling J et al. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:107-166.
Slide I.2
BPHBPHBPHBPH10
8
9.0 40 ml >40 ml
(n=458)
66.1
5.6
4 3.6
3.1
22.3
0(p
BPHBPHBPHBPH80
70 6671
66
(n=90)
60
50 47
40
30
%
20
10
0
Adapted from Sells H et al Br J Urol Int 2000;85:440-445.
Slide II.4
ICBPH guideline
Adapted from Fifth International Consultation 2001 on BPH. In Benign Prostatic Hyperplasia. Plymouth, United Kingdom: Health Publication, 2001:519-535.
Slide IV.3
Slide II.1
( D i T i T l i )-( eg. Doxazosin, Terazosin, Tamsulosin)
5 -Proscar (finasteride)Avodart (dutasteride)
doxazosin finasteride
PROSCAR, finasteride)(AUR)
x
BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol
1. BPHbethanecholfinasteride blocker 3finasteride-blocker 3
2. on Foley
detrusor x
BPHBPHbethanecholbethanechol BPHBPHbethanechol bethanechol
3. DM1
4. DMAUR4. DMAUR
5. NBneurogenic bladderurinary retention on Foleyretention on Foley
x